Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03435250 · ClinicalTrials.gov registry record · Phase 1
Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss
A Phase 1 study, sponsored by Institut de Recherches Internationales Servier.
- Terminated
- Registry status
- Phase 1
- Development phase
- 123
- Enrollment target
NCT03435250 is a Phase 1 study that was terminated before completion, run by Institut de Recherches Internationales Servier. The registered enrollment target is 123 participants.
The verdict
NCT03435250, a Phase 1 study, was terminated before completion, sponsored by Institut de Recherches Internationales Servier.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 123 participants
- Enrollment target
Study Summary
This study will evaluate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of AG-270 in participants with advanced solid tumors or lymphoma with homozygous MTAP deletion.
Interventions
- DRUG nab-paclitaxel
- DRUG docetaxel
- DRUG AG-270
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2018-03-04 |
| Est. Completion | 2023-04-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03435250
The ClinicalTrials.gov registry entry for NCT03435250 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Institut de Recherches Internationales Servier, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which nab-paclitaxel is the first listed.
NCT03435250 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03435250 about?
NCT03435250 is a clinical study titled "Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss". This study will evaluate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of AG-270 in participants with advanced solid tumors or lymphoma with homozygous MTAP deletion.
What is the current status of trial NCT03435250?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 123 participants. The study started on 2018-03-04. Estimated completion is 2023-04-20.
What interventions are being tested in trial NCT03435250?
The interventions under investigation include: nab-paclitaxel (DRUG), docetaxel (DRUG), AG-270 (DRUG).
Who is sponsoring clinical trial NCT03435250?
This trial is sponsored by Institut de Recherches Internationales Servier, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.